Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. DelBene, Suzan K. [D-WA-1]

Rep. DelBene, Suzan K. [D-WA-1]

United States · Official source

Records

3,501 records where Rep. DelBene, Suzan K. [D-WA-1] is listed as a sponsor, author, or other actor. Search with topics and years

Bill· HRH.R. 9169 (119th)referred

PKD Cures Act

United States · United States Congress · 4 June 2026

Resolution· HRESH.Res. 1340 (119th)referred

Expressing strong opposition to the imposition of digital services taxes and other relevant similar measures by other countries that unfairly discriminate against United States companies.

United States · United States Congress · 4 June 2026

This resolution calls on (1) all other countries to cease and desist from implementing any digital services tax (DST) or similar measure, repeal existing DSTs, and immediately stop unfairly targeting U.S. companies; and (2) U.S. government agencies to use all available methods and resources to protect U.S. companies from the discriminatory effects of DSTs. It also supports appropriate tax and trade tools, including Section 301 investigations into the implementation or proposal of DSTs by any nation. (Section 301 of the Trade Act of 1974 authorizes the Office of the U.S. Trade Representative to investigate and take action to enforce U.S. rights under trade agreements and respond to certain foreign trade practices.)

Bill· HRH.R. 9016 (119th)referred

Email Privacy Act

United States · United States Congress · 22 May 2026

Bill· HJRESH.J.Res. 187 (119th)referred

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".

United States · United States Congress · 19 May 2026

This joint resolution prohibits the Centers for Medicare & Medicaid Services (CMS) from testing a new Medicare payment model in certain states that involves a prior authorization process and the use of enhanced technology by third-party contractors to determine whether certain claims should be paid. Specifically, the joint resolution nullifies a notice issued by the CMS on July 1, 2025, titled Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model . (On May 12, 2026, the Government Accountability Office issued a letter of opinion stating that this notice constituted an agency rule and is therefore subject to the Congressional Review Act.) The CMS selected six states to participate in this model over a six-year period: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Under the model, contracted companies must process prior authorization requests (i.e., requests for coverage determinations before a service is furnished) for certain services using enhanced technology (e.g., artificial intelligence). Contracted companies are paid based on the share of resulting savings. The CMS aims to test the model's ability to produce accurate results while streamlining the prior authorization process for Medicare claims. The model is based in part on similar processes used for Medicare Advantage claims.  CMS began implementing the model on January 1, 2026. This joint resolution prohibits the CMS from continuing to do so.

Bill· HRH.R. 8907 (119th)referred

IMPACT to Save Moms Act

United States · United States Congress · 19 May 2026

Innovative Maternal Payment and Coverage To Save Moms Act or the IMPACT to Save Moms Act This bill requires the Centers for Medicare & Medicaid Services to establish the Perinatal Care Alternative Payment Model Demonstration Project through FY2031 to allow states to test payment models for maternity care, including postpartum care, under Medicaid and the Children's Health Insurance Program (CHIP). 

Bill· HRH.R. 8910 (119th)referred

SLUSH FUND Act of 2026

United States · United States Congress · 19 May 2026

Bill· HRH.R. 8811 (119th)referred

Moms Matter Act

United States · United States Congress · 14 May 2026

Resolution· HRESH.Res. 1285 (119th)referred

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

United States · United States Congress · 14 May 2026

Resolution· HRESH.Res. 1252 (119th)passed

Resolution memorializing law enforcement officers killed in the line of duty.

United States · United States Congress · 4 May 2026

This resolution expresses support for police officers and other law enforcement personnel. The resolution further recognizes law enforcement officers across the United States in the pursuit of preserving safe and secure communities; the need to ensure that such officers have the equipment, training, and resources necessary to protect their health and safety while they are protecting the public; and the law enforcement community for acts of sacrifice and heroism. The resolution expresses condolences and appreciation to the loved ones of each law enforcement officer who has made the ultimate sacrifice in the line of duty.

Resolution· HRESH.Res. 1243 (119th)referred

Recognizing the significance of Asian American, Native Hawaiian, and Pacific Islander Heritage Month as an important time to celebrate the significant contributions of Asian Americans, Native Hawaiians, and Pacific Islanders to the history of the United States.

United States · United States Congress · 30 April 2026

This resolution recognizes the significance of Asian American, Native Hawaiian, and Pacific Islander Heritage Month as an important time to celebrate the significant contributions of Asian Americans, Native Hawaiians, and Pacific Islanders to the history of the United States.

Bill· HRH.R. 8425 (119th)referred

Strengthening the Vaccines for Children Program Act of 2026

United States · United States Congress · 21 April 2026

Strengthening the Vaccines for Children Program Act of 2026 This bill expands vaccination programs and coverage for children under Medicaid and the Children's Health Insurance Program (CHIP). Specifically, the bill expands and otherwise modifies the Vaccines for Children Program, which provides free vaccinations to individuals 18 years of age or younger who are uninsured or underinsured (i.e., with limited or no insurance for vaccines), are eligible for Medicaid, or are American Indians or Alaskan Natives. The bill expands the program to include children enrolled in CHIP. The Government Accountability Office must report on the related effects of the bill's changes. The bill also temporarily requires payments under Medicaid and CHIP for vaccine administration and counseling services for children to be made at a rate that is no less than the rate under Medicare for equivalent services. It also increases the Federal Medical Assistance Percentage (i.e., federal matching rate) for states that conduct culturally appropriate outreach regarding the benefits of vaccinations for children.

Bill· HRH.R. 8314 (119th)referred

OPTIONS Act

United States · United States Congress · 15 April 2026

Bill· HRH.R. 8261 (119th)referred

Chronic Care Management Improvement Act of 2026

United States · United States Congress · 14 April 2026

Chronic Care Management Improvement Act of 2026 This bill eliminates cost-sharing for chronic care management services under Medicare.

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.